Pieris Appoints Michael Richman as Supervisory Board Member
FREISING, GERMANY -- (Marketwired) -- 11/12/14 -- Pieris AG announced today the appointment of Michael Richman as a member of its Supervisory Board.
Mr. Richman brings considerable experience to the Pieris Supervisory Board. He currently serves as President and CEO of Amplimmune, Inc., a biologics company focused on cancer and autoimmune diseases that was acquired by Astra Zeneca in 2013. Mr. Richman has a wealth of experience working in research, IP and BD capacities at Chiron Corporation (now Novartis), MedImmune, Inc. (now Astra Zeneca) and MacroGenics. He is a member of the board of directors of Opexa Therapeutics, Inc., and Madison Vaccines, Inc., and was previously a director at Cougar Biotechnology until its acquisition by Johnson & Johnson. Mr. Richman obtained his B.S. in genetics/molecular biology at the University of California at Davis and his M.S.B.A. in international business at San Francisco State University.
"I am delighted to join Pieris, whose Anticalin drug class offers exciting opportunities in the biologics space," commented Mr. Richman. "I look forward to working with management and the rest of the Board to help build on the positive momentum coming from its R&D partnerships." Mr. Chau Q. Khuong of OrbiMed Advisors and Chairman of Pieris' Supervisory Board added, "Michael's extensive experience in business development, M&A and strategic planning for life science companies is an extremely valuable addition to the Pieris Board, and we look forward to working closely with him."
The Company's Board now comprises, in addition to Mr. Richman and Mr. Khuong, Christina Takke of Forbion Capital Partners as Vice-chair.
About Pieris
Pieris is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalins promise to address high-unmet medical needs and expand the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. www.pieris.com.
Additional information is available at www.pieris.com.
Anticalin®, Anticalins® are registered trademarks of Pieris.
For more information, please contact:
Stephen Yoder
CEO
Pieris AG
media@pieris.com
+49 (0) 8161 1411 400
Gretchen Schweitzer
schweitzer@macbiocom.com
+49 172 861 8540
Source: Pieris-AG
Released November 12, 2014